Cirena secured an exclusive license to the University of Colorado Boulder’s thionocarbonate‑based RNA synthesis platform, enabling reliable production of long RNAs (~100–400 nt) with higher yields than phosphoramidite methods. The technology targets CRISPR, functional genomics and advanced RNA therapeutics where long and ultra‑long transcripts are critical. CU Boulder and Cirena framed the deal as opening dependable commercial access to long RNA constructs that have been historically difficult to scale, boosting translational efforts for lncRNA, therapeutic mRNA and CRISPR guide RNAs. Financial terms were not disclosed; university officials and Cirena executives emphasized the potential to accelerate research and commercial programs that require extended RNA payloads. The license addresses a recognized bottleneck for emerging RNA modalities and may accelerate development timelines for programs dependent on long‑RNA delivery.